الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - hjärtsvikt - angiotensin ii-antagonister, kombinationer, medel som påverkar renin-angiotensin-systemet - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - hjärtsvikt - agenter som verkar på renin-angiotensinsystemet - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

novartis europharm limited - brinzolamid, brimonidintartrat - ocular hypertension; glaucoma, open-angle - ögonsjukdomar - sänkning av förhöjt intraokulärt tryck (iop) hos vuxna patienter med öppenvinkelglaukom eller okulär hypertension som monoterapi intraokulära otillräcklig.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemi, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipidmodifierande medel - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

europharma sverige ab - esomeprazolmagnesiumtrihydrat - enterotablett - 20 mg - esomeprazolmagnesiumtrihydrat 22,3 mg aktiv substans; sockersfärer hjälpämne - esomeprazol

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

europharma sverige ab - esomeprazolmagnesiumtrihydrat - enterotablett - 20 mg - esomeprazolmagnesiumtrihydrat 22,3 mg aktiv substans; sockersfärer hjälpämne - esomeprazol

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

europharma sverige ab - esomeprazolmagnesiumtrihydrat - enterotablett - 20 mg - esomeprazolmagnesiumtrihydrat 22,3 mg aktiv substans; sockersfärer hjälpämne - esomeprazol

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

europharma sverige ab - esomeprazolmagnesiumtrihydrat - enterotablett - 40 mg - esomeprazolmagnesiumtrihydrat 44,5 mg aktiv substans; sockersfärer hjälpämne - esomeprazol

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

europharma sverige ab - esomeprazolmagnesiumtrihydrat - enterotablett - 40 mg - esomeprazolmagnesiumtrihydrat 44,5 mg aktiv substans; sockersfärer hjälpämne - esomeprazol